The pharmaceutical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant promise in clinical trials for managing obesity. Unlike some current weight loss treatments, retatrutide appears to offer a more substantial decrease in body size and enhance metabolic health, particular